ERBB2 and non-small cell lung carcinoma: Here, we report a rare case of advanced/metastatic NSCLC with an ERBB2 exon 20 insertion (p.Y772_A775dup) treated with first-line pyrotinib monotherapy, resulting in a durable response and a PFS exceeding 31 months.